<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03367299</url>
  </required_header>
  <id_info>
    <org_study_id>LAL2317</org_study_id>
    <nct_id>NCT03367299</nct_id>
  </id_info>
  <brief_title>Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease Response and Survival in Acute Lymphoblastic Leukemia</brief_title>
  <acronym>LAL2317</acronym>
  <official_title>National Treatment Program With Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease Response and Survival in Philadelphia Chromosome-Negative B-Cell Precursor Adult Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study aims at analyzing the response to treatment of adult patients homogeneously
      treated with supportive care, chemotherapy and blinatumomab.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients with CD19+ Ph- BCP ALL (Philadelphia-negative B-cell precursor acute
      lymphoblastic leukemia) will receive homogeneous supportive care, chemotherapy and
      blinatumomab immunotherapy, and will be homogeneously analyzed for response at prefixed time
      points from induction day 1. For risk-oriented therapy, patients in complete remission (CR)
      will be stratified by risk class according to the diagnostic characteristics and MRD (minimal
      residual disease) study results during early consolidation.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2018</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients that obtain a negative Minimal Residual Disease (MRD)</measure>
    <time_frame>At week 14 from study entry</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients in complete remission (CR)</measure>
    <time_frame>At 32 months from study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients that reach disease-free survial</measure>
    <time_frame>At 32 months from study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients that relapse</measure>
    <time_frame>At 32 months from study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients that dye due to treatment</measure>
    <time_frame>At 32 months from study entry</time_frame>
    <description>Treatment-related mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of serious adverse events</measure>
    <time_frame>At 32 months from study entry</time_frame>
    <description>Safety</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">149</enrollment>
  <condition>Acute Lymphoid Leukemia</condition>
  <condition>Philadelphia Chromosome-Negative B-Cell Precursor</condition>
  <arm_group>
    <arm_group_label>Chemotherapy + Blinatumomab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment sequence consists of eight chemotherapy courses and two blinatumomab courses. Patients not in CR after chemotherapy course 2 will go off-study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy + Blinatumomab</intervention_name>
    <description>Chemotherapy cycles are administered at 21-28 days intervals and each blinatumomab course is 28-day long.</description>
    <arm_group_label>Chemotherapy + Blinatumomab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent according to ICH/EU/GCP and national local laws.

          -  Age 18-65 years.

          -  A diagnosis of untreated Ph- CD19+ BCP ALL is required, either de novo or secondary to
             chemo-radiotherapy for another cancer. Pre-treatment with low-dose corticosteroids in
             patients presenting with hyperleukocytosis is allowed. Before enrolment and pre-phase
             is allowed only in patients presenting with severe, potentially life-threatening
             disease-related clinical symptoms. All diagnostic procedures need to be performed on
             freshly obtained bone marrow (BM) and peripheral blood (PB) samples.

          -  Full cytological, cytochemical, immunophenotypic, cytogenetic and molecular disease
             characterization according to the EGIL and WHO classifications.

          -  BM and PB sampling for MRD evaluations study. Detailed indications on patient
             registration, storage of representative diagnostic material and diagnostic work-up,
             including the shipping of samples for the diagnostic work-up and MRD follow-up studies
             are given in Appendix A.

          -  An ECOG performance status 0-2, unless a performance of 3 is unequivocally caused by
             the disease itself, (and not by pre-existing comorbidities,) and is considered and/or
             documented to be reversible following the application of anti-leukemic therapy and
             appropriate supportive measures.

        Exclusion Criteria:

          -  Diagnosis of Burkitt's leukemia/lymphoma, CD19- BCP ALL, Ph+ ALL, T-ALL, lymphoblastic
             lymphoma (BM involvement by blast cells &lt;25%).

          -  Active CNS leukemia documented by diagnostic lumbar puncture on days -1 to -5 prior to
             the first blinatumomab administration, or any other clinical sign or symptom
             ascribable to symptomatic/documented CNS disease at time of each planned blinatumomab
             course.

          -  Down's syndrome.

          -  A pre-existing, uncontrolled pathology such as heart failure (congestive/ischemic,
             acute myocardial infarction within the past 3 months, untreatable arrhythmias, NYHA
             classes III and IV), severe liver disease with serum bilirubin &gt;3 mg/dL and/or ALT &gt;3
             x upper normal limit (unless attributable to ALL), kidney function impairment with
             serum creatinine &gt;2 mg/dL (unless attributable to ALL), and severe neuropsychiatric
             disorder that impairs the patient's ability to understand and sign the informed
             consent, or to cope with the intended treatment plan. N.B. For altered liver and
             kidney function tests, eligibility criteria can be reassessed at 24-96 hours,
             following the institution of adequate supportive measures.

          -  Presence of serious, active, uncontrolled infections.

          -  Pre-existing HIV positive serology (i.e. already known before enrolment). If HIV
             positivity is detected after enrolment, the patient is put off study.

          -  A history of cancer that is not in a remission phase following surgery and/or
             radiotherapy and/or chemotherapy, with a life expectancy &lt;1 year.

          -  Pregnancy declared by the patient, unless a decision is taken with the patient to
             induce a therapeutic abortion in order to carry on with the ALL therapy. A pregnancy
             test is performed at diagnosis, but does not preclude the enrolment into study.
             Fertile patients will be advised to adopt contraceptive methods while on treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renato Bassan</last_name>
    <role>Study Chair</role>
    <affiliation>Azienda ULSS 12 &quot;Veneziana&quot; U.O. Ematologia Direttore Renato Bassan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roberto Foà</last_name>
    <role>Study Director</role>
    <affiliation>Policlinico Umberto I, Hematology Department.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alessandro Rambaldi</last_name>
    <role>Study Director</role>
    <affiliation>Ospedale di Bergamo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paola Fazi</last_name>
    <phone>+39 0670390514</phone>
    <email>p.fazi@gimema.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Enrico Crea</last_name>
    <phone>+39 0670390514</phone>
    <email>e.crea@gimema.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AOU Ospedali Riuniti Umberto I - G.M. LANCISI - G. SALESI</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivieri</last_name>
    </contact>
    <investigator>
      <last_name>Olivieri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O.C. Ematologia e Terapia Cellulare - Ospedale &quot;C. e G. Mazzoni&quot; di Ascoli Piceno</name>
      <address>
        <city>Ascoli Piceno</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galieni</last_name>
    </contact>
    <investigator>
      <last_name>Galieni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Az.Ospedaliera S.G.Moscati</name>
      <address>
        <city>Avellino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Santoro</last_name>
    </contact>
    <investigator>
      <last_name>Santoro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UO Ematologia con trapianto-Università degli Studi di Bari Aldo Moro</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Specchia</last_name>
    </contact>
    <investigator>
      <last_name>Specchia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UOC Ematologia Ospedale &quot; Monsignor Raffaele Dimiccoli&quot;</name>
      <address>
        <city>Barletta</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tarantini</last_name>
    </contact>
    <investigator>
      <last_name>Tarantini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera - Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rambaldi</last_name>
    </contact>
    <investigator>
      <last_name>Rambaldi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto di Ematologia &quot;Lorenzo e A. Seragnoli&quot; - Policlinico S. Orsola - Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martinelli</last_name>
    </contact>
    <investigator>
      <last_name>Martinelli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spedali Civili - Brescia - Azienda Ospedaliera - U.O. Ematologia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Borlenghi</last_name>
    </contact>
    <investigator>
      <last_name>Borlenghi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia Ospedale A. Perrino</name>
      <address>
        <city>Brindisi</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pastore</last_name>
    </contact>
    <investigator>
      <last_name>Pastore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASL N.8 - Ospedale &quot;A. Businco&quot; - Struttura Complessa di Ematologia e CTMO</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Romani</last_name>
    </contact>
    <investigator>
      <last_name>Romani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università di Catania - Cattedra di Ematologia - Ospedale &quot;Ferrarotto&quot;</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catania</last_name>
    </contact>
    <investigator>
      <last_name>Catania</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S.C. Ematologia ASO S. Croce e Carle</name>
      <address>
        <city>Cuneo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mattei</last_name>
    </contact>
    <investigator>
      <last_name>Mattei</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unità di Ricerca e di Malattie del sangue - Ematologia San Luca Vecchio</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bosi</last_name>
    </contact>
    <investigator>
      <last_name>Bosi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS_AOU San Martino-IST-Ematologia 1-Monoblocco 11°piano- lato ponente</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Beltrami</last_name>
    </contact>
    <investigator>
      <last_name>Beltrami</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UOC di Ematologia con trapianto Ospedale S. Maria Goretti</name>
      <address>
        <city>Latina</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cimino</last_name>
    </contact>
    <investigator>
      <last_name>Cimino</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE</name>
      <address>
        <city>Lecce</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Di Renzo</last_name>
    </contact>
    <investigator>
      <last_name>Di Renzo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UOS Ematologia Ospedale Versilia ATNO</name>
      <address>
        <city>Lido Di Camaiore</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Simonetti</last_name>
    </contact>
    <investigator>
      <last_name>Simonetti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.U. - Policlinico G. Martino Messina Oncologia Medica - U.O.C. Ematologia</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Musolino</last_name>
    </contact>
    <investigator>
      <last_name>Musolino</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. di Ematologia- Ospedale dell'Angelo - Mestre</name>
      <address>
        <city>Mestre</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bassan</last_name>
    </contact>
    <investigator>
      <last_name>Bassan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico UOC Oncoematologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cortelezzi</last_name>
    </contact>
    <investigator>
      <last_name>Cortelezzi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Niguarda &quot; Ca Granda&quot; - SC Ematologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mancini</last_name>
    </contact>
    <investigator>
      <last_name>Mancini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia e Trapianto di MIdollo - Ist.Scientifico Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UO Ematologia - AOU Policlinico di Modena</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luppi</last_name>
    </contact>
    <investigator>
      <last_name>Luppi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Rilievo Nazionale &quot;A. Cardarelli&quot;</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ferrara</last_name>
    </contact>
    <investigator>
      <last_name>Ferrara</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Napoli &quot;Federico II&quot; - Facoltà di Medicina e Chirurgia</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pane</last_name>
    </contact>
    <investigator>
      <last_name>Pane</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S.C.D.U. Ematologia - Università del Piemonte Orientale Amedeo Avogadro</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lunghi</last_name>
    </contact>
    <investigator>
      <last_name>Lunghi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. CTMO Ematologia - Osp. S.Francesco</name>
      <address>
        <city>Nuoro</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Latte</last_name>
    </contact>
    <investigator>
      <last_name>Latte</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S.C.D.U.Medicina Interna a indirizzo ematologico</name>
      <address>
        <city>Orbassano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rege Cambrin</last_name>
    </contact>
    <investigator>
      <last_name>Rege Cambrin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Padova - Ematologia ed Immunologia Clinica</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gurrieri</last_name>
    </contact>
    <investigator>
      <last_name>Gurrieri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncoematologia -plesso ospedaliero &quot;A. Tortora&quot; di Pagani</name>
      <address>
        <city>Pagani</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Califano</last_name>
    </contact>
    <investigator>
      <last_name>Califano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti &quot;Villa Sofia-Cervello&quot;</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabbiano</last_name>
    </contact>
    <investigator>
      <last_name>Fabbiano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Day Hospital dell'U.O.C di Ematologia e CTMO Padiglione 1</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roti</last_name>
    </contact>
    <investigator>
      <last_name>Roti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S.C. Ematologia - Fondazione IRCCS Policlinico S. Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zappasodi</last_name>
    </contact>
    <investigator>
      <last_name>Zappasodi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sezione di Ematologia ed Immunologia Clinica - Ospedale S.Maria della Misericordia</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martelli</last_name>
    </contact>
    <investigator>
      <last_name>Martelli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia Clinica - Azienda USL di Pescara</name>
      <address>
        <city>Pescara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sborgia</last_name>
    </contact>
    <investigator>
      <last_name>Sborgia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia - AUSL Ospedale G. da Saliceto</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ciceri</last_name>
    </contact>
    <investigator>
      <last_name>Ciceri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia - AUSL Ospedale G. da Saliceto</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vallisa</last_name>
    </contact>
    <investigator>
      <last_name>Vallisa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento Emato-Oncologia A.O.&quot;Bianchi-Melacrino-Morelli&quot;</name>
      <address>
        <city>Reggio Calabria</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martino</last_name>
    </contact>
    <investigator>
      <last_name>Martino</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;Infermi&quot;</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Miannulli</last_name>
    </contact>
    <investigator>
      <last_name>Mianulli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Az. Ospedaliera &quot;Sant' Andrea&quot;-Università la Sapienza II Facoltà di Medicina e Chirurgia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tafuri</last_name>
    </contact>
    <investigator>
      <last_name>Tafuri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complesso Ospedaliero S. Giovanni Addolorata</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chierichini</last_name>
    </contact>
    <investigator>
      <last_name>Chierichini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Padiglione Cesalpino - I piano - Divisione di Ematologia - Ospedale S. Camillo</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mancini</last_name>
    </contact>
    <investigator>
      <last_name>Mancini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S.C. di Ematologia e Trapianti - I.F.O. Istituto Nazionale Tumori Regina Elena</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Spadea</last_name>
    </contact>
    <investigator>
      <last_name>Spadea</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O.C. Ematologia - Ospedale S. Eugenio</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>De Fabritiis</last_name>
    </contact>
    <investigator>
      <last_name>Roma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università Cattolica del Sacro Cuore - Policlinico A. Gemelli</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sica</last_name>
    </contact>
    <investigator>
      <last_name>Sica</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università degli Studi &quot;Sapienza&quot; - Dip Biotecnologie Cellulari - Divisione di Ematologia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Foà</last_name>
    </contact>
    <investigator>
      <last_name>Foà</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università degli Studi - Policlinico di Tor Vergata</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Del Principe</last_name>
    </contact>
    <investigator>
      <last_name>Del Principe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento Oncologico - Ospedale S.Maria delle Croci</name>
      <address>
        <city>Rondoni</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ravenna</last_name>
    </contact>
    <investigator>
      <last_name>Ravenna</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sezione di Ematologia Cancer Center Humanitas</name>
      <address>
        <city>Rozzano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rozzano</last_name>
    </contact>
    <investigator>
      <last_name>Rozzano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UOC di Ematologia - AOU San Giovanni di Dio e Ruggi D'Aragona</name>
      <address>
        <city>Salerno</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Selleri</last_name>
    </contact>
    <investigator>
      <last_name>Selleri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cascavilla</last_name>
    </contact>
    <investigator>
      <last_name>Cascavilla</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia dell'Università di Torino - &quot;Città della Salute e della Scienza&quot;</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ferrero</last_name>
    </contact>
    <investigator>
      <last_name>Ferrero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ematologia e Terapie Cellulari- A.S.O. Ordine Mauriziano, P.O. Umberto I-Ospedale</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cignetti</last_name>
    </contact>
    <investigator>
      <last_name>Cignetti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S.C. Ematologia 2 A.O. Città della Salute e della Scienza di Torino San Giovanni Battista</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Audisio</last_name>
    </contact>
    <investigator>
      <last_name>Audisio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Ematologica-Centro Trapianti e Terapie cellulari AOU,</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Candoni</last_name>
    </contact>
    <investigator>
      <last_name>Candoni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituti Ospitalieri di Verona- Div. di Ematologia - Policlinico G.B. Rossi</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bonifacio</last_name>
    </contact>
    <investigator>
      <last_name>Bonifacio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ULSS N.6 Osp. S. Bortolo</name>
      <address>
        <city>Vicenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Di Bona</last_name>
    </contact>
    <investigator>
      <last_name>Di Bona</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.gimema.it</url>
    <description>GIMEMA Foundation website</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2017</study_first_submitted>
  <study_first_submitted_qc>December 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2017</study_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Lymphoid Leukemia</keyword>
  <keyword>Philadelphia Chromosome-Negative B-Cell Precursor</keyword>
  <keyword>Adults</keyword>
  <keyword>Minimal residual disease</keyword>
  <keyword>Blinatumomab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Philadelphia Chromosome</mesh_term>
    <mesh_term>Neoplasm, Residual</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blinatumomab</mesh_term>
    <mesh_term>Antibodies, Bispecific</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

